ACIP Expands RSV Vaccine Recommendation to At‑Risk Adults Aged 50–59 Years

©MargJohnsonVA/AdobeStock

The CDC’s Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, to expand its guidance to recommend respiratory syncytial virus (RSV) vaccination for adults aged 50 to 59 years who are at increased risk for severe RSV‑associated lower respiratory tract disease (LRTD).1

"I don't think I can say it enough, but [we need] more studies in moderate-to-severe immunocompromised patients who are at highest risk for RSV disease," ACIP member Mini Kamboj, MD, of Weill Cornell Medical College, in New York City, said after she voted for the recommendation. This is "a call to action," Dr Kamboj said in the April 16, 2025, meeting.1

Wednesday’s action builds on ACIP’s June 2024 vote to recommend RSV vaccination for adults aged 60–74 years at increased risk and all adults aged 75 years and older.2

According to the CDC, RSV causes an estimated 15 000–20 000 hospitalizations annually among US adults aged 50–59 years, with the highest risk observed in those with underlying conditions such as obesity, cardiovascular disease, diabetes, COPD, and asthma. A separate systematic review estimated approximately 42 000 hospitalizations each year in adults aged 50–64 years, adjusted for under‑detection.

Three RSV vaccines are currently approved in the US for adults aged 60 years and older: GSK’s Arexvy and Pfizer’s Abrysvo (both protein subunit vaccines) and Moderna’s mResvia (messenger RNA vaccine). Arexvy is additionally approved for use in adults aged 50 to 59 years who have underlying medical conditions that increase their risk for severe RSV disease. Abrysvo also is approved for prevention of LRTD caused by RSV in adults ages 18 to 59 years who are at increased risk, and for immunization in pregnancy at 32 to 36 weeks' gestational age for the prevention of LRTD caused by RSV in infants from birth through 6 months. Moderna has submitted an application to the FDA to extend mResVax to adults aged 18 to 59 years, with a decision expected by June 12, 2025.

“With its vote to expand adult RSV vaccination recommendations, ACIP has taken an important step toward protecting individuals aged 50 to 59 who have underlying medical conditions that increase their risk for severe RSV illness,” Alejandro Cane, Vice President, Vaccines and Antivirals US Medical Lead, Pfizer, said in a press release.3 “We are proud that ABRYSVO has the broadest indication among RSV vaccines, covering older adults, adults 18 and older at heightened risk of severe disease, and pregnant women to help protect infants.”

Tony Wood, chief scientific officer at GSK, added in a press release, “We are pleased with ACIP's recommendation to expand the benefits of RSV [immunization] to more than 13 million adults aged 50-59 who are at increased risk for the severe consequences of this virus.”4

The ACIP also voted unanimously to recommend that GSK's pentavalent MenABCWY (Penmenvy) meningococcal vaccine "may be used when both MenACWY and MenB are indicated at the same visit." The recommendation would apply to "healthy persons ages 16 to 23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccine; and persons aged 10 years and older who are at increased risk for meningococcal disease (eg, because of persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia)." Committee members approved a similar recommendation for the Vaccines For Children program.1

ACIP recommendations are not considered final until they are published in the Morbidity and Mortality Weekly Report.

References:

1. Advisory Committee on Immunization Practices. ACIP Live Stream April 16, 2025. YouTube. April 16, 2025. Accessed April 17, 2025. https://www.youtube.com/live/zN4ACg2mEzw

2. Halsey G. ACIP revises recommendation for adult RSV vaccination. Patient Care Online. June 27, 2024. https://www.patientcareonline.com/view/acip-revises-recommendation-for-adult-rsv-vaccination

3. ACIP votes to expand recommendation for Pfizer's RSV vaccine ABRYSVO® to include adults aged 50 to 59 at increased risk of disease. Pfizer. News item. April 16, 2025. Accessed April 17, 2025. https://www.pfizer.com/news/press-release/press-release-detail/acip-votes-expand-recommendation-pfizers-rsv-vaccine

4. Arexvy recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices. GSK. News item. April 16, 2025. Accessed April 17, 2025. https://www.gsk.com/en-gb/media/press-releases/arexvy-recommended-for-adults-aged-50-59-at-increased-risk-for-severe-respiratory-syncytial-virus-rsv-disease-by-us-advisory-committee-on-immunization-practices/